While the coronavirus has impacted millions of Americans across the United States, it has hit the elderly population particularly hard. In fact, more than 40 percent of coronavirus deaths in the U.S. have been linked to long-term care facilities, according to a New York Times survey. In an effort to bring those numbers down, pharmaceutical company Eli Lilly, in partnership with the National Institutes of Health (NIH), has just launched a late-stage antibody treatment trial focusing on residents and staff at nursing homes.
"COVID-19 has had a devastating impact on nursing home residents," Lilly's chief scientific officer Daniel Skovronsky said in a statement. "We're working as fast as we can to create medicines that might stop the spread of the virus to these vulnerable individuals."
The trial is expected to enroll up to 2,400 participants who live or work at a facility and have recently been diagnosed with the disease. The trial will evaluate the safety and success of using LY-CoV555, a potent, neutralizing antibody that works against the spike protein of the novel coronavirus. The trial will look at whether a single dose of the antibody treatment reduces the rate of infection over four weeks as well as symptoms over eight weeks.
"The importance of these kinds of therapies for people like the elderly or immunocompromised is that they can provide the hope and the safety net that these people really need right now," said Andrew Adams, vice president of new therapeutic modalities & COVID-19 research at Eli Lilly, who is overseeing the trial. "I think people in those populations are really desperate and looking for something to help with the coronavirus."
Eli Lilly is taking its trial on the road with customized mobile research units that can travel directly to areas that are experiencing outbreaks.
"This is an interesting solution, to bring the medicine to these vulnerable patients," said Adams. "This lets us be flexible and move these trials around the country, tracking these trials as we come across them."
Adams said he is hoping Eli Lilly will have results on the efficacy of these antibodies in the fourth quarter of this year. Even if successful, though, he says research for a vaccine needs to continue.
"These have to be thought of as more of a bridge, where a vaccine provides long-term protection in terms of years of immunity, where we will provide hopefully in the range of months with these types of treatments. We hope this to be a short-term bridge to the long-term effective vaccination," he said.
A new report from Dr. Michael Worobey alleges that it is likely that COVID-19 originated from a raccoon dog at the Wuhan live animal market in China. While his report does not rule out the coronavirus could have escaped from a lab, Worobey's evidence points to a natural origin.
Jill and Carlo are back to cover the latest in the Rittenhouse trial, new information on the origins of Covid, return-to-office and more.
JOIN US FOR THE YOUTUBE WATCH PARTY @ 9aET: http://www.youtube.com/cheddarnow
Over the weekend, Russia fired a missile at one of its own satellites, triggering an explosion that launched thousands of pieces of shrapnel through space and forced the astronauts aboard the International Space Station to shelter in place. Senior Writer from Space.com Chelsea 'Foxanne' Gohd, joined Cheddar to discuss more.
Gerald Comissiong, CEO of Todos Medical, joins None of the Above to discuss why we're seeing surges of COVID-19 cases in Europe, the potential for a winter surge of COVID-19, the benefits of high vaccination rates in a community, and the coming COVID treatment pills.
Cognitive healthcare platform BrainCheck recently raised $10 million in a Series B round. The platform offers neurologists a new way to detect and care for brain disorders like Alzeheimer's, and brain injuries like concussions. BrainCheck CEO Yael Katz joined Cheddar News' Closing Bell to discuss.
On this episode of Cheddar Innovates: Ice Barrel CEO breaks down the physical and mental health benefits to cold therapy training; Dishcraft CEO explains how its robotics is transforming the role of a dishwasher in restaurant kitchens; A look at Curiosity Stream's original series 'The Year That Rocked The World.'
Jill Wagner is joined by Baker to talk about kids and vaccines: we finally know how many young kids are getting vaccinated. Plus, Democrats are working on a Plan B for paid family leave. And the salad chain Sweetgreen goes public.
A breakthrough deal between the U.S. and China when it comes to climate has finally been reached. The two countries have pledged to work together to curb carbon emissions. Amy Harder, executive editor at Cipher, joined Cheddar News to discuss more.
Joey Roulette, space reporter for The New York Times, joined Cheddar to break down the intense backlash Russia is seeing after its missile test sent destroyed a non-functioning satellite and sent thousands of pieces of debris potentially at the ISS, endangering astronauts onboard. He said while the blast happened days ago, there is still some risk to the station as the space junk threat remains. So far, the U.S., NATO, and the European Union have condemned Russia for the test.
Jill is joined by “Friend of the Pod” Mosheh Oinounou to talk booster shots, and whether “fully vaccinated” will eventually mean three shots, not two. Plus, the latest on the Kyle Rittenhouse trial. And the research is in: we know now the perfect way to hug. Also, Jill and Mosheh debate whether Airpods are passé.
